CADTH Canadian Drug Expert Committee final recommendation indication: asthma. Omalizumab -- resubmission (Xolair -- Novartis Pharmaceuticals Canada Inc.)

Ejemplares similares

• CADTH Canadian Drug Expert Committee recommendation : indication : diabetes mellitus, type 2. Ertugliflozin/Metformin (Segluromet -- Merck Canada Inc.)
  por: Canadian Agency for Drugs and Technologies in Health,
  Publicado: (2019)
• CADTH Canadian Drug Expert Committee recommendation : indication : Parkinson's disease. Apomorphine hydrochloride (Movapo -- Paladin Labs Inc.)
  por: Canadian Agency for Drugs and Technologies in Health,
  Publicado: (2018)
• CADTH Canadian Drug Expert Committee recommendation : indication : chronic hepatitis C virus infection. Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi -- Gilead Sciences Canada, Inc.)
  por: Canadian Agency for Drugs and Technologies in Health,
  Publicado: (2018)
• CADTH Canadian Drug Expert Committee final recommendation Edoxaban : Lixiana-Servier Canada Inc. : indication : venous thromboembolic events
  por: Canadian Agency for Drugs and Technologies in Health,
  Publicado: (2017)
• CADTH Canadian Drug Expert Committee recommendation : indication : the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. Nitisinone (MDK-Nitisinone - )
  por: Canadian Agency for Drugs and Technologies in Health,
  Publicado: (2018)